Nanose Medical

Millions of people remain undiagnosed with lung cancer and MASH, contributing to lung and liver cancers ranking among the top three deadliest worldwide—largely due to late detection. Currently, there are no accurate, non-invasive, and widely accessible screening tools available for early detection of lung cancer and MASH.

NaNose fills this critical gap with a fast, accessible device designed for population-level screening and risk stratification. Our portable, non-invasive platform uses nanotechnology and AI to detect volatile biomarkers in breath, creating a unique “fingerprint” for early detection of lung cancer and MASH.

Backed by thousands of breath samples and clinical data from 10 sites across Europe and Israel, our technology has demonstrated over 80% diagnostic accuracy in early trials—showcasing its strong potential as a low-cost, scalable point-of-care tool. Our work is supported by the EU Horizon (LUCIA consortium), EIC Transition grant for ReLiV project, Israeli Innovation Authority, and Google AI Fund.